Trends in endpoint use in pivotal trials and efficacy for US Food and Drug Administration–approved solid tumor therapies, 1995-2021

BACKGROUND: Many cancer therapies are now approved based on surrogate endpoints such as progression-free survival (PFS) to ensure that patients have speedy access to life-saving cancer medicines. However, the link between surrogate endpoints and overall survival (OS) is not well established in many...

Descripción completa

Detalles Bibliográficos
Autores principales: Alabaku, Orges, Laffey, Taylor N, Suh, Kangho, Li, Meng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2022
Materias:
Research Brief
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10372986/
https://www.ncbi.nlm.nih.gov/pubmed/36282934
http://dx.doi.org/10.18553/jmcp.2022.28.11.1219

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10372986/
https://www.ncbi.nlm.nih.gov/pubmed/36282934
http://dx.doi.org/10.18553/jmcp.2022.28.11.1219

Ejemplares similares